Skip to content
Review Open access

Efficacy and safety of GLP-1 receptor agonists in patients with schizophrenia spectrum disorders treated with antipsychotics: a systematic review and meta-analysis.

Oct 2026 · European Neuropsychopharmacology · Vol 114, pp. 113886 · 0 citations · 62 references
Medicine

Abstract

Weight gain and impaired glucose metabolism are common complications of antipsychotic treatment in schizophrenia spectrum disorders (SSD). While beneficial in other populations, the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in SSD remain unclear. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating GLP-1 RAs versus placebo in SSD patients treated with antipsychotics. PubMed, Scopus, and Web of Science were searched until January 2026. Random-effects models were used to pool mean differences (MDs), standardized mean differences (SMDs), and risk ratios (RRs), as appropriate. Seven RCTs including 481 participants were included. Compared with placebo, GLP-1 RAs significantly reduced body weight (MD -6.98 kg; 95% CI -10.53 to -3.43), BMI (MD -2.51 kg/m²; 95% CI -3.51 to -1.51), waist circumference (MD -5.05 cm; 95% CI -6.66 to -3.44), HbA1c (MD -0.32 percentage points; 95% CI -0.38 to -0.26), and fasting blood glucose (MD -0.54 mmol/L; 95% CI -0.83 to -0.25). Heterogeneity was substantial for body weight (I²=93%) and BMI (I²=80%). No significant effects emerged for blood pressure or lipid parameters. Psychiatric symptom severity did not differ between GLP-1 RAs and placebo (SMD -0.05; 95% CI -0.36 to 0.25). Gastrointestinal adverse events were more frequent with GLP-1 RAs than with placebo, while overall study drop-out did not differ between groups. GLP-1 RAs improve short-term anthropometric and glycemic outcomes in SSD patients treated with antipsychotics. However, the limited number of trials, substantial heterogeneity in weight-related outcomes, and relatively short follow-up warrant cautious interpretation and further large-scale RCTs.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.